XML 54 R45.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION (Details) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Total revenues $ 41,015 $ 78,671
Cost of revenues (excluding amortization and depreciation) 13,558 9,156
Research and development expense (excluding share-based compensation expense):    
Research and development expense (excluding share-based compensation expense): 406,288 105,668
General and administrative expense (excluding stock based compensation and amortization expense) 622,948 645,719
Amortization 4,786 2,662
Stock-based compensation 636,844 161,349
Professional fees 367,816 227,829
Interest income, net (1,103) (304)
Equity in net (income) loss from equity method investees 1,048 (5,783)
Other income (22,833) (26,468)
Segment net loss (1,988,337) (1,041,157)
Reconciliation of net loss    
Adjustments and reconciling items
Consolidated net loss (1,988,337) (1,041,157)
Clinical Trials [Member]    
Research and development expense (excluding share-based compensation expense):    
Research and development expense (excluding share-based compensation expense): 79,402 1,238
H A L O Design [Member]    
Research and development expense (excluding share-based compensation expense):    
Research and development expense (excluding share-based compensation expense): 298,037 103,477
S Y N C Project [Member]    
Research and development expense (excluding share-based compensation expense):    
Research and development expense (excluding share-based compensation expense): 23,713
Other Research And Development [Member]    
Research and development expense (excluding share-based compensation expense):    
Research and development expense (excluding share-based compensation expense): $ 5,136 $ 953